Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative products to enhance cancer care. The company focuses on drug candidates in the initial clinical trials for cancer treatment. Initially, the company concentrated on developing PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor for the treatment of patients with HER2-positive metastatic breast cancer.